Home/ Supplements/ Niacin/ Guggul 250

Guggul 250

product on market Capsule Wonder Laboratories Safety: 92/100
92/100

This product looks safe

  • Niacin: 125mg is 3.6× the Tolerable Upper Intake Level (35mg)
  • 60% of ingredients have research evidence
C Label Compliance Grade

What the Evidence Says

AI-generated · Qwen 3.6 · methodology

Guggul and chromium are associated with lipid and glucose metabolism, though evidence for Guggul remains limited. Niacin and potassium support cardiovascular and metabolic functions with moderate to strong research backing. Ginger root extract is commonly used for digestive support.

AI-generated summary based on research evidence. Not medical advice.

Alerts

Safety Alerts

Niacin: 125mg is 3.6× the Tolerable Upper Intake Level (35mg)

Label

Product Label

Label for Guggul 250
Open Full PDF View on NIH DSLD →
Details

Label Data

1 Capsule(s)
Serving Size
100
Servings
Botanical with Nutrients
Product Type
60%
Evidence Coverage
Ingredients

Supplement Facts — Evidence Check

125 mg (625% DV)
Exceeds UL by 3.6× (UL: 35 mg) 196 studies (A:5, B:63)
25 mcg (20.8% DV)
Within RDA (0.7× RDA) 199 studies (A:1, B:55)
Potassium
11 mg (1% DV)
Gugul extract
125 mg
Market median: 250.0mg (337 products) 127 studies (A:1, B:41)

Other Ingredients

Vegetable Cellulose Gelatin Calcium Carbonate Vegetable Magnesium Stearate
Claims

Label Claims — Verification

Unverified All Other
Unverified Structure/Function
Info

Product Information

Directions for Use

Directions: As a dietary supplement, take 1 capsule three times daily.

Warnings & Precautions

Tamper evident: Do not use this product if imprinted foil seal under cap is broken or missing.

Keep out of reach of children.

Warning: Diabetics/Hypoglycemics use only under a doctor's supervision.

If you are pregnant or nursing, consult your physician before taking this product.

Formulation Notes

Mfg. in an FDA Registered Facility using Good Manufacturing Practices (GMPs)

Conforms to USP <2091> for weight. Meets USP <2040> disintegration for maximum bioavailability.

Standardized 2.5% Gugulsterones

Helps maintain cholesterol levels that are already within normal range

Gluten free

Made in USA

Additional Information

Keep tightly closed. Store at room temperature: 59 degrees - 86 degrees F (15 degrees to 30 degrees C).

Formula 868

Was a tablet now a capsule

Metadata

Product Details

DSLD Entry Date2021-11-19
Product TypeBotanical with Nutrients
FormCapsule
DSLD ID260897
Data Updated2026-04-11
Research

Research Evidence

241
Research Sources
55
Avg Quality
113
Meta Analysis
75
Systematic Review
32
Rct
11
Clinical Trial
3
Other
3
Regulatory Source
1
Cochrane Review
1
Narrative Review
1
Openfda Safety
A Niacin for primary and secondary prevention of cardiovascular events
Meta Analysis The Cochrane database of systematic reviews 2017 PubMed DOI
A Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases
Meta Analysis BMJ (Clinical research ed.) 2013 PubMed DOI
A Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients
Meta Analysis BMJ (Clinical research ed.) 2014 PubMed DOI
A A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk
Meta Analysis Nature medicine 2024 PubMed DOI
A Meta-analysis and imputation refines the association of 15q25 with smoking quantity
Meta Analysis Nature genetics 2010 PubMed DOI
A Genome-wide meta-analyses identify multiple loci associated with smoking behavior
Meta Analysis Nature genetics 2010 PubMed DOI
A Antidepressants for smoking cessation
Meta Analysis The Cochrane database of systematic reviews 2014 PubMed DOI
A Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha-hydroxy acid) for acne
Meta Analysis The Cochrane database of systematic reviews 2020 PubMed DOI
B Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis
Meta Analysis JAMA network open 2019 PubMed DOI
B Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis
Meta Analysis JAMA 2016 PubMed DOI
View all evidence for Niacin →
Compare

Similar Products

View all Niacin products →

This product page is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before taking any supplement.